Liu Li-Sheng
Zhonghua Xin Xue Guan Bing Za Zhi. 2011 Jul;39(7):579-615.
The 2010 Chinese guidelines for the management of hypertension is an update of the previous versions in 2005 and 1999. A guideline committee of nearly 100 members appointed by the Chinese Hypertension League (CHL) and the National Centre for Cardiovascular Disease (NCCD), in collaboration with the Chinese societies of cardiology, nephrology, neurology, gynecology and endocrinology, convened on several occasions and discussed the guidelines, drafted by a core writing group. The prevalence of hypertension has been increasing in China for decades, and reached 18.8% in the year 2002. The rates of awareness, treatment and control for hypertension patients remain low compared to high income countries, in spite of substantial improvements since 1991. In some communities, the control rate of hypertension increased up to 60%. The mortality rate of stroke, which is the major complication of hypertension in the Chinese population, gradually decreased during the period, more so in urban areas than in rural areas for the middle-aged and elderly populations; in the younger age groups, however, it increased. As hypertension is a "cardiovascular syndrome", the management strategy should be based on the overall risk of cardiovascular disease estimated with all related risk factors, target organ damage and co-morbidity of patients. The target blood pressure is set at SBP/DBP < 140/90 mm Hg (1 mm Hg = 0. 133 kPa) in uncomplicated hypertension; < 150/90 mm Hg for the elderly (> or = 65 years) or, if tolerable, < 140/90 mm Hg; and < 130/80 mm Hg for those with diabetes, coronary heart disease or renal disease. For these high risk patients, the management should be individualised. In general, lifestyle modification, such as sodium restriction, smoking cessation, moderation of body weight and alcohol consumption, and increasing dietary potassium intake and physical activity, should be implemented for prevention and control of hypertension. Five classes of antihypertensive drugs, including calcium channel blockers, angiotensin converting enzyme inhibitors, angiotensin type II receptor blockers, diuretics and beta-blockers, as well as single pill combinations of these agents, can be used for initial and maintenance of antihypertensive treatment. Several populations require special attention in the prevention and control of hypertension, such as children and adolescents, the elderly, pregnant women, and patients with various cardiovascular complications. Since health-care policies and resources vary substantially from one place to another, two levels of recommendations of management are proposed: a sophisticated and a basic, allowing doctors-in-charge to manage their patients in a more feasible way.
《2010年中国高血压防治指南》是2005年和1999年旧版指南的更新版。由中国高血压联盟(CHL)和国家心血管病中心(NCCD)任命的近100名成员组成的指南委员会,与中国心脏病学、肾脏病学、神经病学、妇产科学和内分泌学学会合作,多次召开会议并讨论了由一个核心写作小组起草的指南。几十年来,中国高血压患病率一直在上升,2002年达到18.8%。尽管自1991年以来有了显著改善,但与高收入国家相比,高血压患者的知晓率、治疗率和控制率仍然较低。在一些社区,高血压控制率提高到了60%。在中国人群中,作为高血压主要并发症的卒中死亡率在此期间逐渐下降,中老年人群中城市地区下降幅度大于农村地区;然而,在较年轻年龄组中,卒中死亡率却有所上升。由于高血压是一种“心血管综合征”,管理策略应基于综合考虑患者所有相关危险因素、靶器官损害和合并症所评估的心血管疾病总体风险。对于无并发症的高血压患者,目标血压设定为收缩压/舒张压<140/90 mmHg(1 mmHg = 0.133 kPa);对于老年人(≥65岁),目标血压为<150/90 mmHg,若能耐受则为<140/90 mmHg;对于患有糖尿病、冠心病或肾病的患者,目标血压为<130/80 mmHg。对于这些高危患者,管理应个体化。一般而言,应通过采取如限钠、戒烟、控制体重和饮酒量、增加膳食钾摄入量以及进行体育活动等生活方式干预措施来预防和控制高血压。五类降压药物,包括钙通道阻滞剂、血管紧张素转换酶抑制剂、血管紧张素Ⅱ受体阻滞剂、利尿剂和β受体阻滞剂,以及这些药物的单片复方制剂,均可用于高血压的初始治疗和维持治疗。在高血压的预防和控制中,有几类人群需要特别关注,如儿童和青少年、老年人、孕妇以及患有各种心血管并发症的患者。由于各地医疗保健政策和资源差异很大,因此提出了两个层面的管理建议:一个是精细版,一个是基本版,以便主管医生能够以更可行的方式管理患者。